{"a":[{"_":"Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact","$":{"href":"/biotech/genentech-doubles-down-adc-resistant-cancers-1b-dualitybio-pact","hreflang":"en"}}]}

Summary

Roche's Genentech entered into a partnership with DualityBio to develop antibody-drug conjugates for patients resistant to ADC treatments, with $45 million upfront and over $1 billion in potential milestones.